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In cancer, the epidermal growth factor (EGF) receptor (EGFR) can be activated by mutations that 
disrupt the inactive conformation and allow the active conformation to predominate. Structural 
studies have elucidated the molecular events that lead to EGFR activation and shown that small-
molecule anti-EGFR drugs can bind to either the inactive or the active conformation of the kinase 
domain. In this issue of Cancer Cell, Yun et al. present 12 crystal structures of the wild-type or mutant 
forms of the EGFR kinase domain bound to four different ligands. This study will prove invaluable to 
those developing novel anti-EGFR drugs.The epidermal growth factor (EGF) 
receptor (EGFR) is a membrane-
spanning receptor tyrosine kinase 
(RTK) that regulates cell proliferation, 
survival, and migration (Hynes and 
Lane, 2005). EGFR is implicated in You put the C helix in, the C helix out,
In out, in out, you move it all about,
You do the Hokey-Cokey and you turn around
And that’s what it’s all about . . .
Adapted from www.bbc.co.uk/cbeebies/ 
tweenies/songtime/songs/h/hokeycokey.shtmlnon-small-cell lung cancer (NSCLC), 
glioblastoma, and breast cancer, 
where its oncogenic potential is 
stimulated by protein overexpression 
or by somatic gain-of-function muta-
tions (Hynes and Lane, 2005). Small 
deletions/insertions that affect the 
critical “C helix,” or point mutations 
that affect the “glycine-rich loop” or 
the “activation segment” occur in 
10%–20% of NSCLC cases (Lynch et 
al., 2004; Paez et al., 2004). The most 
common mutation (?40% of NSCLC 
cases) is an arginine for leucine sub-
stitution at position 858 (L858R), but 
surprisingly, it is the presence of a 
mutation such as this that determines 
patient responses to drugs such as 
gefitinib and erlotinib. This is unex-
pected because these small-molecule 
drugs were developed to target over-
expressed wild-type EGFR (EGFRWT) and not the mutated proteins (Lynch 
et al., 2004; Paez et al., 2004).
EGFR regulation has been intensely 
studied, particularly by structural 
biologists. EGF binds to the extra-
cellular domain, inducing receptor dimerization, stimulating the kinase 
activity, and resulting in autophos-
phorylation of the cytosolic domain, 
although activation segment phos-
phorylation is not required for kinase 
activity (Stamos et al., 2002). Rather, 
cytosolic domain phosphorylation 
produces binding sites for other pro-
teins, forming a signaling complex 
that regulates cell functions. 
Structural studies have revealed 
two conformations of the EGFR kinase 
domain: active and inactive (Stamos et 
al., 2002; Wood et al., 2004; Zhang et 
al., 2006). In each, the kinase domain 
adopts a typical kinase fold, with two 
lobes separated by the catalytic cleft 
(Figure 1), but in the inactive confor-
mation the kinase domain is thought 
to be intrinsically autoinhibited. When 
EGF binding induces receptor dimer-
ization, the local concentration of the Cancer Cell kinase domain at the plasma mem-
brane is effectively increased (Zhang 
et al., 2006). This stimulates the for-
mation of asymmetric kinase domain 
dimers, in which the C lobe of one of 
the monomer (monomer B) binds to 
the N lobe of the other (monomer A). 
In this dimer, monomer B acts as an 
allosteric activator of monomer A by 
inducing several structural changes, 
one of which is to “push” the C helix 
of monomer A into the correct posi-
tion for catalysis (Zhang et al., 2006). 
This elegant model explains how 
EGFR is activated.
Notably, most of the published 
structures of the EGFR kinase domain 
are in the active conformation. This 
is partly because some drugs only 
bind to the active conformation, but 
also because the high concentration 
of protein required for crystallization 
studies induces the formation of the 
asymmetric units normally induced by 
receptor dimerization, thereby forc-
ing monomer A into the active con-
formation. The inactive conformation 
is only observed in crystals formed 
by kinase domains that cannot form 
dimers (due to the introduction of 
carefully selected mutations), or when 
the domain binds to inhibitors such 
as lapatinib, which only binds to the 
inactive conformation (Wood et al., 
2004; Zhang et al., 2006). However, 
this conformation is highly instruc-
tive, because in it the activation seg-
ment forms a short helix that inserts 11, March 2007 ©2007 Elsevier Inc. 209
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PreviewsFigure 1. Comparison of the Inactive and Active Conformations of the EGFR 
Kinase Domain
(A) Inactive EGFR kinase domain from the structure bound to lapatinib (removed for clarity) is 
shown (coordinates published in Wood et al. [2004]). 
(B) Active EGFR kinase domain from the structure bound to erlotinib (removed for clarity) is shown 
(coordinates published in Stamos et al. [2002]). In each case the position of the N lobe, the C 
lobe, and the catalytic cleft are indicated. The C helix regions are highlighted in orange, and the 
activation segments are in red. The kinases are aligned with each other such that their C lobes 
are in the same relative orientation. This reveals a subtle twist in the relative orientations of the N 
lobes and the insertion of the activation segment behind the C helix in the inactive (A) structure.into a hydrophobic pocket behind the 
C helix (Figure 1). This disrupts the 
alignment of the C helix and is a key 
feature of the inactive kinase. L858 
inserts into the hydrophobic pocket, 
and structural studies suggest that 
the larger, charged side chain of argi-
nine could not be accommodated. 
The arginine is therefore predicted to 
disrupt the inactive conformation of 
EGFR, leading to the conclusion that 
EGFR mutations do not so much acti-
vate the kinase as disrupt the inac-
tive conformation. This allows the C 
helix to occupy the correct position 
for catalytic activity, thereby favor-
ing the active conformation (Zhang 
et al., 2006). This is similar to the 
protein kinase BRAF, which is also 
activated by mutations that destabi-
lize the inactive conformation (Wan et 
al., 2004), and suggests that inactive 
conformation destabilization could 
be a common mechanism by which 
cancer mutations to activate kinases.
In this issue of Cancer Cell, Yun 
and coworkers add to this fast-mov-
ing story by presenting the struc-
tures of the kinase domain of EGFRWT 
and two gefitinib-sensitive mutants, 
L858R and G719S (a glycine-rich 210 Cancer Cell 11, March 2007 ©2007 loop mutant) bound to the ATP ana-
log AMP-PNP and three small-mol-
ecule inhibitors, gefitinib, AEE788 
(a pyrrolopyrimidine), and AFN941 
(a staurosporine analog) (Yun et al., 
2007). All 12 structures adopt the 
active conformation, confirming that 
L858R and G719S cause minimal 
disruption to the protein backbone 
in the active state and suggest-
ing that glycine-rich loop mutations 
also activate EGFR by destabilizing 
the inactive conformation. Yun et 
al. demonstrate that EGFRG719S and 
EGFRL858R are activated 10- and 50-
fold, respectively, which is consistent 
with the theoretical contribution that 
these residues make to the stability 
of the inactive conformation. Also, 
the higher-activity EGFRL858R is more 
sensitive to gefitinib and AEE788 
than the lower-activity EGFRG719S. 
It is suggested that this is a reflec-
tion of the fact that these inhibitors 
only bind to the active conforma-
tion. However, this is a circular argu-
ment. If the inhibitors only bind to 
the active conformation, why then 
do they not bind to activated EGFRWT 
in cells and inhibit it similarly to the 
mutants? This may simply reflect the Elsevier Inc.length of time that the wild-type pro-
tein spends in the active conforma-
tion, and because it can exchange 
between active and inactive confor-
mations, it can displace the inhibi-
tors, allowing ATP to rebind and thus 
retain some catalytic activity.
Many of the regulation concepts 
described by Yun et al. have been 
discussed elsewhere, but this paper 
is important in the information it 
provides to those developing EGFR 
inhibitors. Inhibitors that bind to 
the active receptor have more rapid 
binding and dissociation kinetics 
than those that bind to the inactive 
conformation. Presumably this is 
because active conformation bind-
ers simply bind to the pre-existing 
cavity and therefore must only com-
pete with ATP. In contrast, inhibitors 
that bind to the inactive kinase do so 
through an induced fit. This requires 
opening of the kinase domain, dis-
placement of the resident ATP, com-
petition with ATP, and then refolding 
of the domain around the inhibitor, all 
of which takes longer and requires 
significantly more association and 
dissociation energy. The perceived 
advantage of targeting the inactive 
conformation is that the inhibitors 
should be more selective, because 
whereas all active kinases adopt 
more or less the same shape, inac-
tive kinases exist in a variety of struc-
tures, providing more opportunity to 
develop selective compounds.
An important conclusion from these 
studies is that drugs that bind to the 
active conformation will favor mutated 
EGFR, whereas those that bind to the 
inactive kinase will only inhibit wild-type 
EGFR or those mutants that can be 
forced into the inactive conformation. 
Accordingly, it would be interesting to 
use structural approaches to see if lap-
atinib can force a substituted arginine 
at position 858 into the hydrophobic 
pocket behind the C helix in the inactive 
conformation. Furthermore, the obser-
vation that gefitinib binds to EGFRL858R, 
but not EGFRWT or EGFRG719S, through 
two distinct modes and that AFN941 
binds to EGFRG719S through a distinct 
mechanism compared to EGFRWT and 
EGFRL858R is also interesting, as it sug-
gests the possibility of making muta-
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Previewstion-specific inhibitors. Patient strati-
fication and matching the drug to the 
mutation will be an important strategy to 
ensure successful treatment of malig-
nancies such as NSCLC. Furthermore, 
most patients on prolonged gefitinib 
and erlotinib treatment develop sec-
ondary mutations in the EGFR kinase 
domain that block drug binding, lead-
ing to clinical resistance and therapy 
failure (Kobayashi et al., 2005; Kwak et 
al., 2005; Pao et al., 2005). The ability 
to synthesize drugs that inhibit through 
different binding modes will be cru-
cial if we are to tackle this increasingly 
important clinical problem. Finally, the 
information learned for the EGFR will 
have important ramifications for other 
kinases, such as BCR-ABL, which also 
binds to drugs in either the active and 
inactive conformations (Liu and Gray, 
2006; Schindler et al., 2000).Among the many problems of cancer 
research, “cell-of-origin” questions 
may occasionally be viewed as trivial 
or semantic. Yet tumors are not born 
equal: for example, pancreatic duc-
tal adenocarcinomas (PDACs) nearly 
always arise from precursors that sus-
tain activating KRAS mutations, while 
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